



Metabolic traits and stroke risk in individuals of African ancestry: 
Mendelian randomization analysis 
 
TABLE OF CONTENTS 
SUPPLEMENTARY METHODS ................................................................................................................. 2 
GENETIC ASSOCIATION ESTIMATES .................................................................................................... 2 
MENDELIAN RANDOMIZATION ........................................................................................................... 3 
MEASURING STATISTICAL EVIDENCE .................................................................................................. 3 
SUPPLEMENTARY TABLE I ...................................................................................................................... 4 
SUPPLEMENTARY TABLE II ..................................................................................................................... 5 
SUPPLEMENTARY TABLE III .................................................................................................................... 6 
SUPPLEMENTARY FIGURE I .................................................................................................................... 7 
SUPPLEMENTARY FIGURE II ................................................................................................................... 8 
SUPPLEMENTARY FIGURE III .................................................................................................................. 9 
SUPPLEMENTARY FIGURE IV ................................................................................................................ 10 
SUPPLEMENTARY FIGURE V ................................................................................................................. 11 









GENETIC ASSOCIAITON ESTIMATES 
AFRICAN ANCESTRY INDIVIDUALS 
For the metabolic traits used as exposures, genetic association estimates for populations of 
African ancestries were obtained from a genome-wide association study (GWAS) meta-
analysis of the African Partnership for Chronic Disease Research (APCDR, N=13,612), 
Black participants in the UKBiobank (N=6,614) and African ancestry individuals from in the 
Million Veteran Program (MVP, N=57,332). APCDR data used here consists of four cohorts 
from Sub-Saharan Africa: The Uganda Genome Resource (UGR), The Durban Diabetes 
Study (DDS), The Durban Case Control Study (DCC), The Africa America Diabetes Mellitus 
Study (AADM)16. UKBiobank is a prospective study of approximately 500,000 UK 
residents20, and MVP is an observational cohort study of US military force veterans21. 
We used GWAS summary data from Consortium of Minority Population Genome-Wide 
Association Studies of Stroke (COMPASS) to obtain genetic association estimates with the 
risk of ischemic stroke (IS)10. COMPASS comprises a total of 22,051 individuals of African 
descent with either a physician-adjudicated stroke (N=3,734) or no history of stroke 
(N=18,317). This consortium includes participants from 13 cohorts which include: 
prospective cohorts (ARIC study [Atherosclerosis Risk in Communities], CHS 
[Cardiovascular Health Study], JHS [Jackson Heart Study], the WHI [Women’s Health 
Initiative]; case-control studies (INTERSTROKE, REGARDS [Reasons for Geographic and 
Racial Differences in Stroke], ISGS [Ischemic Stroke Genetics Study], VISP [Vitamin 
Intervention for Stroke Prevention], SLESS [South London Ethnicity and Stroke Study], the 
GEOS Study [Genetics of Early Onset Stroke], the NINDS-SiGN [National Institute of 
Neurological Disorders and Stroke–Stroke Genetics Network], HANDLS [Healthy Aging in 
Neighborhoods of Diversity Across the Life Span]); and an affected sib pair study—SWISS 
(Siblings With Ischemic Stroke Study).  This consortium defined stroke as a focal 
neurological deficit of presumed vascular cause with a sudden onset and lasting 24 hours or 
until death with clinical or radiological (computed tomography/magnetic resonance imaging) 
evidence with stroke diagnosis made when there is overwhelming clinical evidence in the 
absence of radiological evidence of a cerebral infarction. They only considered first 
(incident) clinically validated ischemic strokes. Individuals with a baseline history of 
ischemic or hemorrhagic stroke were excluded10. 
 
EUROPEAN ANCESTRY INDIVIDUALS 
We obtained genetic associations with the risk of IS in European ancestry individuals from 
the MEGASTROKE consortium (34,217 cases, 406,111 controls)13. This includes cohorts 
from the Australian Stroke Genetics Collaborative (ASGC), Bio-Repository of DNA in 
Stroke (BRAINS), Genetics of Early Onset Stroke (GEOS) Study, Heart Protection Study 
(HPS), Ischemic Stroke Genetics Study (ISGS)/ Siblings With Ischemic Stroke Study 
(SWISS), MGH Genes Affecting Stroke Risk and Outcome Study (MGH-GASROS), Milano, 
Wellcome Trust Case-Control Consortium 2 (WTCCC2), VISP, WHI - The Women’s Health 






The main Mendelian randomization (MR) analyses estimating the association of genetically 
proxied levels of each exposure with risk of IS were performed using the random-effects 
inverse-variance weighted (IVW) method15. The IVW method combines the effect estimates 
from each individual genetic variant (computed as the ratio of the variant-IS association to 
the variant-exposure association). We also examined the evidence for differences in the MR 
estimates between populations of European and African ancestries. The standard error (SE) 
for the difference was estimated using the propagation of error method: 
𝑆𝐸(𝛽𝐸𝑈𝑅 − 𝛽𝐴𝐹𝑅) = √𝑆𝐸(𝛽𝐸𝑈𝑅)2 + 𝑆𝐸(𝛽𝐴𝐹𝑅)2, 
where 𝛽𝐸𝑈𝑅 and 𝛽𝐴𝐹𝑅 are the MR estimates in European and African ancestry populations, 
respectively. 
 
IVW method provides a statistically consistent estimator of the true causal effect as long as 
all genetic variants are valid instrumental variables, fulfilling the following three 
assumptions: First, the genetic instruments are strongly predictive of cardiometabolic 
disorder. Second, the association of genetic instruments with the risk of IS is not confounded. 
Last, the effect of the genetic instrument on the risk of IS should be fully mediated via 
cardiometabolic disorder under investigation15. If any of the genetic variants are invalid 
instruments due to pleiotropy (where the variant affects IS risk through pathways unrelated to 
the exposure), the IVW estimator is still statistically consistent as long as the pleiotropy is 
balanced (that is, the average of the pleiotropic effects of each genetic variant on the outcome 
are equal to zero).  
 
Sensitivity analyses for MR were performed using the weighted median method, a weighted 
mode-based method, the contamination mixture method, and the MR-Egger method15. Each 
of these methods provides a statistically consistent estimate of the true causal effect under 
different sets of assumptions. The MR-Egger method allows all genetic variants to be invalid 
but requires the pleiotropic effects that relate to the risk of IS through pleiotropic pathways to 
be uncorrelated with the genetic variant-exposure associations. Weighted median provides a 
consistent estimate if at least half of the weights are provided by valid instrumental variables. 
Both weighted mode and contamination mixture method rely on the zero modal pleiotropy 
assumption, i.e. the largest weights among different homogeneous subsets should be provided 
by valid instrumental variables. 
 
MEASURING STATISTICAL EVIDENCE 
To guide the interpretation of the results, a Bonferroni-corrected significance level for five 
exposures is 0.05/5 = 0.01. However, the statistical evidence is interpreted in light of the 
effect sizes, their confidence intervals, and the consistency of the results in the sensitivity 
analyses, and we refrain from categorizing results as ‘significant’ or ‘non-significant’ based 





Supplementary Table I. Genetic variants used as instrumental variables for each exposure. 
T2DM: type 2 diabetes mellitus; HDL: high-density lipoprotein, LDL: low-density 
lipoprotein; TC: Total cholesterol; TG: triglycerides; AFR: association estimates in 
populations of African ancestries; EUR: association estimates in populations of European 
ancestries; CHR: chromosome; POS: position; EA: effect allele; NEA: non-effect allele. See 
separate Excel file.  
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Supplementary Table II. Mendelian Randomization odds ratios (OR) and 95% confidence 
intervals (CI) on the risk of stroke per one standard deviation increase in the exposure, using 
different MR methods. Con-Mix: Contamination mixture; IVW: random-effects Inverse-
variance weighted; HDL: high-density lipoprotein, LDL: low-density lipoprotein; TG: 
triglycerides; TC: Total cholesterol; Median: weighted median-based estimate; Mode: 
weighted mode-based estimate; MR-Egger: Mendelian Randomization Egger; T2DM: type 2 




Supplementary Table III. Comparison of Mendelian Randomization odds ratios (OR) and 
their 95% confidence intervals (CI) per standard deviation increase in the exposure (per 
doubling the odds of type 2 diabetes mellitus [T2DM]) on the risk of ischemic stroke between 
populations of African and European ancestries. HDL-C: high-density lipoprotein 
cholesterol, LDL-C: low-density lipoprotein cholesterol; TC: Total cholesterol; TG: 
triglycerides. 
 African European  
Exposure OR (95% CI) OR (95% CI) P-value for difference 
T2DM 1.15 (1.05 – 1.26) 1.09 (1.07 – 1.11) 0.28 
HDL-C 0.83 (0.70 – 0.98) 0.93 (0.89 – 0.99) 0.19 
LDL-C 1.18 (1.03 – 1.34) 1.12 (1.04 – 1.21) 0.53 
TC 1.23 (1.06 – 1.43) 1.06 (0.98 – 1.15) 0.08 
TG 1.23 (0.98 – 1.55) 1.06 (1.01 – 1.11) 0.21 




Supplementary Figure I: Forest plot showing Mendelian randomization sensitivity analysis 
estimates for the association between cardiometabolic traits and risk of ischemic stroke. 
Results are given as point estimates and their 95% confidence intervals per standard deviation 
increase in genetically proxied levels of the exposure for continuous traits and per doubling 
of the odds for genetically proxied type 2 diabetes mellitus (T2DM) liability. HDL-C: high-
density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol; TC: Total 
cholesterol; TG: triglycerides; IVW-RE: random-effects inverse-variance weighted; MR-




Supplementary Figure II. A scatterplot of instrumental variable genetic association estimates for 
type 2 diabetes risk (log-odds, x-axis) and ischemic stroke risk (log-odds, y-axis) in Mendelian 
randomization (MR) analysis, separately for African and European ancestries, with lines added for 
MR results using different methods. The slope of each line corresponds to the effect size obtained 
by the corresponding MR method. The size of each data point corresponds to the precision of the 
variant-outcome effect size estimate. IVW-RE: random-effects Inverse-variance weighted; MR-







Supplementary Figure III. A scatterplot of instrumental variable genetic association estimates for 
high-density lipoprotein cholesterol (x-axis) and ischemic stroke risk (log-odds, y-axis) in 
Mendelian randomization (MR) analysis, separately for African and European ancestries, with lines 
added for MR results using different methods. The slope of each line corresponds to the effect size 
obtained by the corresponding MR method. The size of each data point corresponds to the precision 
of the variant-outcome effect size estimate. IVW-RE: random-effects Inverse-variance weighted; 









Supplementary Figure IV. A scatterplot of instrumental variable genetic association estimates for 
low-density lipoprotein cholesterol (x-axis) and ischemic stroke risk (log-odds, y-axis) in 
Mendelian randomization (MR) analysis, separately for African and European ancestries, with lines 
added for MR results using different methods. The slope of each line corresponds to the effect size 
obtained by the corresponding MR method. The size of each data point corresponds to the precision 
of the variant-outcome effect size estimate. IVW-RE: random-effects Inverse-variance weighted; 








Supplementary Figure V. A scatterplot of instrumental variable genetic association estimates for 
total cholesterol (x-axis) and ischemic stroke risk (log-odds, y-axis) in Mendelian randomization 
(MR) analysis, separately for African and European ancestries, with lines added for MR results 
using different methods. The slope of each line corresponds to the effect size obtained by the 
corresponding MR method. The size of each data point corresponds to the precision of the variant-
outcome effect size estimate. IVW-RE: random-effects Inverse-variance weighted; MR-Egger: 





Supplementary Figure VI. A scatterplot of instrumental variable genetic association estimates for 
triglycerides (x-axis) and ischemic stroke risk (log-odds, y-axis) in Mendelian randomization (MR) 
analysis, separately for African and European ancestries, with lines added for MR results using 
different methods. The slope of each line corresponds to the effect size obtained by the 
corresponding MR method. The size of each data point corresponds to the precision of the variant-
outcome effect size estimate. IVW-RE: random-effects Inverse-variance weighted; MR-Egger: 
Mendelian randomization Egger; ConMix: contamination mixture method. 
